---
document_datetime: 2025-12-29 09:09:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/tavlesse.html
document_name: tavlesse.html
version: success
processing_time: 0.1068486
conversion_datetime: 2025-12-30 01:55:07.408525
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Tavlesse

[RSS](/en/individual-human-medicine.xml/67273)

##### Authorised

This medicine is authorised for use in the European Union

fostamatinib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Tavlesse](#news-on)
- [More information on Tavlesse](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Tavlesse is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked.

Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body's defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily.

Tavlesse contains the active substance fostamatinib.

Expand section

Collapse section

## How is Tavlesse used?

Tavlesse can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the treatment of blood diseases. It is available as tablets.

The recommended starting dose for Tavlesse is 100 mg twice daily and the doctor then adjusts the dose according to the patient's platelet count and the medicine's side effects. The maximum dose is 150 mg twice daily. Treatment is stopped after 12 weeks if the platelet count does not rise enough to prevent bleeding. The doctor may interrupt treatment or stop it permanently if certain side effects occur.

For more information about using Tavlesse, see the package leaflet or contact your doctor or pharmacist.

## How does Tavlesse work?

Fostamatinib, the active substance in Tavlesse, blocks the activity of the enzyme spleen tyrosine kinase (SYK). This enzyme is involved in stimulating parts of the immune system. By blocking SYK's activity, fostamatinib reduces the immune system's destruction of platelets, so allowing the platelet count to rise, which reduces the likelihood of excessive bleeding.

## What benefits of Tavlesse have been shown in studies?

Tavlesse was found effective in two main studies involving a total of 150 patients with chronic immune thrombocytopenia. The platelet count was stable and above an acceptable level in 17% of patients taking Tavlesse for 24 weeks compared with 2% of patients receiving placebo (a dummy treatment).

## What are the risks associated with Tavlesse?

The most common side effects with Tavlesse (which may affect more than 1 in 10 people) are dizziness, high blood pressure, frequent bowel movement and diarrhoea, nausea (feeling sick) and blood tests showing liver changes. Serious side effects (which may affect about 1 in 100 people) are febrile neutropenia (low white blood cell count with fever), diarrhoea, pneumonia (lung infection), and hypertensive crisis (dangerous rise in blood pressure).

Women must not take Tavlesse during pregnancy. For the full list of side effects and restrictions, see the package leaflet.

## Why is Tavlesse authorised in the EU?

Tavlesse was found modestly effective for patients with immune thrombocytopenia when other treatments had not worked well enough and for whom there is no alternative treatment. Tavlesse can have serious side effects but they can be managed by taking precautions and reducing the dose. The European Medicines Agency therefore decided that Tavlesse's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Tavlesse?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tavlesse have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Tavlesse are continuously monitored. Side effects reported with Tavlesse are carefully evaluated and any necessary action taken to protect patients.

## Other information about Tavlesse

Tavlesse received a marketing authorisation valid throughout the EU on 09 January 2020.

Tavlesse : EPAR - Medicine overview

Reference Number: EMA/628301/2019

English (EN) (119.51 KB - PDF)

**First published:** 11/02/2020

[View](/en/documents/overview/tavlesse-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-620)

български (BG) (143.32 KB - PDF)

**First published:**

11/02/2020

[View](/bg/documents/overview/tavlesse-epar-medicine-overview_bg.pdf)

español (ES) (118.39 KB - PDF)

**First published:**

11/02/2020

[View](/es/documents/overview/tavlesse-epar-medicine-overview_es.pdf)

čeština (CS) (139.83 KB - PDF)

**First published:**

11/02/2020

[View](/cs/documents/overview/tavlesse-epar-medicine-overview_cs.pdf)

dansk (DA) (118.86 KB - PDF)

**First published:**

11/02/2020

[View](/da/documents/overview/tavlesse-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.92 KB - PDF)

**First published:**

11/02/2020

[View](/de/documents/overview/tavlesse-epar-medicine-overview_de.pdf)

eesti keel (ET) (106.66 KB - PDF)

**First published:**

11/02/2020

[View](/et/documents/overview/tavlesse-epar-medicine-overview_et.pdf)

ελληνικά (EL) (140.54 KB - PDF)

**First published:**

11/02/2020

[View](/el/documents/overview/tavlesse-epar-medicine-overview_el.pdf)

français (FR) (119.32 KB - PDF)

**First published:**

11/02/2020

[View](/fr/documents/overview/tavlesse-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.61 KB - PDF)

**First published:**

11/02/2020

[View](/hr/documents/overview/tavlesse-epar-medicine-overview_hr.pdf)

italiano (IT) (118.56 KB - PDF)

**First published:**

11/02/2020

[View](/it/documents/overview/tavlesse-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (146.37 KB - PDF)

**First published:**

11/02/2020

[View](/lv/documents/overview/tavlesse-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (137.65 KB - PDF)

**First published:**

11/02/2020

[View](/lt/documents/overview/tavlesse-epar-medicine-overview_lt.pdf)

magyar (HU) (138.8 KB - PDF)

**First published:**

11/02/2020

[View](/hu/documents/overview/tavlesse-epar-medicine-overview_hu.pdf)

Malti (MT) (140.08 KB - PDF)

**First published:**

11/02/2020

[View](/mt/documents/overview/tavlesse-epar-medicine-overview_mt.pdf)

Nederlands (NL) (119.22 KB - PDF)

**First published:**

11/02/2020

[View](/nl/documents/overview/tavlesse-epar-medicine-overview_nl.pdf)

polski (PL) (141.72 KB - PDF)

**First published:**

11/02/2020

[View](/pl/documents/overview/tavlesse-epar-medicine-overview_pl.pdf)

português (PT) (119.38 KB - PDF)

**First published:**

11/02/2020

[View](/pt/documents/overview/tavlesse-epar-medicine-overview_pt.pdf)

română (RO) (136.81 KB - PDF)

**First published:**

11/02/2020

[View](/ro/documents/overview/tavlesse-epar-medicine-overview_ro.pdf)

slovenčina (SK) (140.22 KB - PDF)

**First published:**

11/02/2020

[View](/sk/documents/overview/tavlesse-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.6 KB - PDF)

**First published:**

11/02/2020

[View](/sl/documents/overview/tavlesse-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.04 KB - PDF)

**First published:**

11/02/2020

[View](/fi/documents/overview/tavlesse-epar-medicine-overview_fi.pdf)

svenska (SV) (117.42 KB - PDF)

**First published:**

11/02/2020

[View](/sv/documents/overview/tavlesse-epar-medicine-overview_sv.pdf)

Tavlesse : EPAR - Risk management plan

English (EN) (18.3 MB - PDF)

**First published:** 11/02/2020

**Last updated:** 02/12/2024

[View](/en/documents/rmp-summary/tavlesse-epar-risk-management-plan_en.pdf)

## Product information

Tavlesse : EPAR - Product information

English (EN) (282.77 KB - PDF)

**First published:** 11/02/2020

**Last updated:** 02/12/2024

[View](/en/documents/product-information/tavlesse-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-451)

български (BG) (442.09 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/bg/documents/product-information/tavlesse-epar-product-information_bg.pdf)

español (ES) (287.79 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/es/documents/product-information/tavlesse-epar-product-information_es.pdf)

čeština (CS) (363.51 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/cs/documents/product-information/tavlesse-epar-product-information_cs.pdf)

dansk (DA) (308.67 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/da/documents/product-information/tavlesse-epar-product-information_da.pdf)

Deutsch (DE) (299.89 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/de/documents/product-information/tavlesse-epar-product-information_de.pdf)

eesti keel (ET) (283.48 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/et/documents/product-information/tavlesse-epar-product-information_et.pdf)

ελληνικά (EL) (435.61 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/el/documents/product-information/tavlesse-epar-product-information_el.pdf)

français (FR) (292.16 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/fr/documents/product-information/tavlesse-epar-product-information_fr.pdf)

hrvatski (HR) (322.67 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/hr/documents/product-information/tavlesse-epar-product-information_hr.pdf)

íslenska (IS) (273.84 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/is/documents/product-information/tavlesse-epar-product-information_is.pdf)

italiano (IT) (314.63 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/it/documents/product-information/tavlesse-epar-product-information_it.pdf)

latviešu valoda (LV) (369.47 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/lv/documents/product-information/tavlesse-epar-product-information_lv.pdf)

lietuvių kalba (LT) (371.3 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/lt/documents/product-information/tavlesse-epar-product-information_lt.pdf)

magyar (HU) (332.36 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/hu/documents/product-information/tavlesse-epar-product-information_hu.pdf)

Malti (MT) (357.25 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/mt/documents/product-information/tavlesse-epar-product-information_mt.pdf)

Nederlands (NL) (292.44 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/nl/documents/product-information/tavlesse-epar-product-information_nl.pdf)

norsk (NO) (280.49 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/no/documents/product-information/tavlesse-epar-product-information_no.pdf)

polski (PL) (366.97 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/pl/documents/product-information/tavlesse-epar-product-information_pl.pdf)

português (PT) (286.51 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/pt/documents/product-information/tavlesse-epar-product-information_pt.pdf)

română (RO) (349.07 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/ro/documents/product-information/tavlesse-epar-product-information_ro.pdf)

slovenčina (SK) (363.71 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/sk/documents/product-information/tavlesse-epar-product-information_sk.pdf)

slovenščina (SL) (325.85 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/sl/documents/product-information/tavlesse-epar-product-information_sl.pdf)

Suomi (FI) (285.91 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/fi/documents/product-information/tavlesse-epar-product-information_fi.pdf)

svenska (SV) (282.08 KB - PDF)

**First published:**

11/02/2020

**Last updated:**

02/12/2024

[View](/sv/documents/product-information/tavlesse-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0018 13/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Tavlesse : EPAR - All authorised presentations

English (EN) (11.2 KB - PDF)

**First published:** 11/02/2020

[View](/en/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-768)

български (BG) (53.64 KB - PDF)

**First published:**

11/02/2020

[View](/bg/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.94 KB - PDF)

**First published:**

11/02/2020

[View](/es/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.06 KB - PDF)

**First published:**

11/02/2020

[View](/cs/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (47.13 KB - PDF)

**First published:**

11/02/2020

[View](/da/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (46.66 KB - PDF)

**First published:**

11/02/2020

[View](/de/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.22 KB - PDF)

**First published:**

11/02/2020

[View](/et/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (62.57 KB - PDF)

**First published:**

11/02/2020

[View](/el/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_el.pdf)

français (FR) (46.46 KB - PDF)

**First published:**

11/02/2020

[View](/fr/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.06 KB - PDF)

**First published:**

11/02/2020

[View](/hr/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.15 KB - PDF)

**First published:**

11/02/2020

[View](/is/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.11 KB - PDF)

**First published:**

11/02/2020

[View](/it/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (61.88 KB - PDF)

**First published:**

11/02/2020

[View](/lv/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.11 KB - PDF)

**First published:**

11/02/2020

[View](/lt/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (62.04 KB - PDF)

**First published:**

11/02/2020

[View](/hu/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.32 KB - PDF)

**First published:**

11/02/2020

[View](/mt/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.12 KB - PDF)

**First published:**

11/02/2020

[View](/nl/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.26 KB - PDF)

**First published:**

11/02/2020

[View](/no/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_no.pdf)

polski (PL) (55.81 KB - PDF)

**First published:**

11/02/2020

[View](/pl/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.94 KB - PDF)

**First published:**

11/02/2020

[View](/pt/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_pt.pdf)

română (RO) (53.76 KB - PDF)

**First published:**

11/02/2020

[View](/ro/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (62.47 KB - PDF)

**First published:**

11/02/2020

[View](/sk/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (63.01 KB - PDF)

**First published:**

11/02/2020

[View](/sl/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.09 KB - PDF)

**First published:**

11/02/2020

[View](/fi/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.73 KB - PDF)

**First published:**

11/02/2020

[View](/sv/documents/all-authorised-presentations/tavlesse-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Tavlesse Active substance Fostamatinib disodium International non-proprietary name (INN) or common name fostamatinib Therapeutic area (MeSH) Thrombocytopenia Anatomical therapeutic chemical (ATC) code B02BX

### Pharmacotherapeutic group

Other systemic hemostatics

### Therapeutic indication

Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

## Authorisation details

EMA product number EMEA/H/C/005012 Marketing authorisation holder

Instituto Grifols S.A.

C/ Can Guasch, 2

Marketing authorisation issued 09/01/2020 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Tavlesse : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.39 KB - PDF)

**First published:** 05/05/2020

**Last updated:** 02/12/2024

[View](/en/documents/procedural-steps-after/tavlesse-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Tavlesse-H-C-PSUSA-00010819-202010 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/500312/2021

English (EN) (123.34 KB - PDF)

**First published:** 10/09/2021

[View](/en/documents/scientific-conclusion/tavlesse-h-c-psusa-00010819-202010-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Tavlesse : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/654949/2019

English (EN) (11.96 MB - PDF)

**First published:** 11/02/2020

[View](/en/documents/assessment-report/tavlesse-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tavlesse

Adopted

Reference Number: EMA/CHMP/536390/2019

English (EN) (116.35 KB - PDF)

**First published:** 15/11/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tavlesse_en.pdf)

#### News on Tavlesse

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 (updated)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019-updated) 15/11/2019

#### More information on Tavlesse

- [EMEA-001196-PIP03-21 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001196-pip03-21)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 02/12/2024

## Share this page

[Back to top](#main-content)